PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 5715人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1254995, encodeId=b53e125499586, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet：Pembrolizumab可单药治疗低PD-L1 TPS的晚期非小细胞肺癌, objectType=article, longId=163734, objectId=df88163e345a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df88163e345a, replyNumber=0, likeNumber=49, createdTime=2019-04-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df88163e345a, moduleTitle=Lancet：Pembrolizumab可单药治疗低PD-L1 TPS的晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df88163e345a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254994, encodeId=218812549944f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：PD-L1基因变异对淋巴瘤PD-1封闭疗法耐药性的影响, objectType=article, longId=163654, objectId=47c616365415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47c616365415, replyNumber=0, likeNumber=63, createdTime=2019-04-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47c616365415, moduleTitle=Blood：PD-L1基因变异对淋巴瘤PD-1封闭疗法耐药性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47c616365415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254993, encodeId=a5a01254993b4, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的AKT抑制剂ipatasertib联合PD-L1单抗和紫杉醇，显示出对三阴性乳腺癌的治疗前景, objectType=article, longId=163592, objectId=c75b163592a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c75b163592a1, replyNumber=0, likeNumber=96, createdTime=2019-04-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c75b163592a1, moduleTitle=罗氏的AKT抑制剂ipatasertib联合PD-L1单抗和紫杉醇，显示出对三阴性乳腺癌的治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c75b163592a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254992, encodeId=4ace1254992d3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=北大BMJ重磅！AIDS是降低全球健康期望寿命的首要原因！NEJM连发2文，PD-1/PD-L1联合治疗大PK！, objectType=article, longId=163567, objectId=d50316356e4c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50316356e4c, replyNumber=0, likeNumber=15, createdTime=2019-04-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50316356e4c, moduleTitle=北大BMJ重磅！AIDS是降低全球健康期望寿命的首要原因！NEJM连发2文，PD-1/PD-L1联合治疗大PK！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50316356e4c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254991, encodeId=48bd125499108, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=宝刀尚未老，新剑已开锋——PD-1/PD-L1抑制剂的现状和新机遇, objectType=article, longId=163480, objectId=b6cb163480f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6cb163480f2, replyNumber=0, likeNumber=61, createdTime=2019-04-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6cb163480f2, moduleTitle=宝刀尚未老，新剑已开锋——PD-1/PD-L1抑制剂的现状和新机遇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6cb163480f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254990, encodeId=e09c1254990f3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nature Biomedical Engineering：PD-L1棕榈酰化修饰及相应抑制剂开发策略, objectType=article, longId=163298, objectId=544316329842, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=544316329842, replyNumber=0, likeNumber=53, createdTime=2019-04-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=544316329842, moduleTitle=Nature Biomedical Engineering：PD-L1棕榈酰化修饰及相应抑制剂开发策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=544316329842)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254989, encodeId=f89b1254989ed, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cancer Immunology Research：发现靶向PD-L1的癌症免疫治疗新途径, objectType=article, longId=163295, objectId=1a09163295f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a09163295f2, replyNumber=0, likeNumber=57, createdTime=2019-04-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a09163295f2, moduleTitle=Cancer Immunology Research：发现靶向PD-L1的癌症免疫治疗新途径, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a09163295f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254988, encodeId=779a12549882a, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=张伟教授：PD-L1检测，挑战重重，任重道远, objectType=article, longId=163017, objectId=452e16301e77, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=452e16301e77, replyNumber=0, likeNumber=68, createdTime=2019-03-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=452e16301e77, moduleTitle=张伟教授：PD-L1检测，挑战重重，任重道远, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=452e16301e77)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254987, encodeId=0831125498ef9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Commun：吸烟有益免疫治疗？反了！中国科学家发现香烟烟雾会诱导PD-L1表达，帮助癌细胞逃避免疫, objectType=article, longId=162996, objectId=f87a162996f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f87a162996f8, replyNumber=0, likeNumber=81, createdTime=2019-03-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f87a162996f8, moduleTitle=Nat Commun：吸烟有益免疫治疗？反了！中国科学家发现香烟烟雾会诱导PD-L1表达，帮助癌细胞逃避免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f87a162996f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254986, encodeId=1a91125498637, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, objectType=article, longId=162148, objectId=423a1621482c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=423a1621482c, replyNumber=0, likeNumber=119, createdTime=2019-03-13, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=423a1621482c, moduleTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=423a1621482c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254985, encodeId=c91c1254985a8, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, objectType=article, longId=161940, objectId=45871619401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45871619401a, replyNumber=0, likeNumber=60, createdTime=2019-03-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45871619401a, moduleTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45871619401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254984, encodeId=ae60125498449, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Haematol：抗PD-1或抗PD-L1诱发血液系统不良事件罕见, objectType=article, longId=161615, objectId=4282161615c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4282161615c8, replyNumber=0, likeNumber=101, createdTime=2019-03-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4282161615c8, moduleTitle=Haematol：抗PD-1或抗PD-L1诱发血液系统不良事件罕见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4282161615c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254983, encodeId=7f8e1254983e7, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=群雄逐鹿下PD-1/PD-L1专利布局策略, objectType=article, longId=160287, objectId=9fc716028ee8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fc716028ee8, replyNumber=0, likeNumber=66, createdTime=2019-02-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fc716028ee8, moduleTitle=群雄逐鹿下PD-1/PD-L1专利布局策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fc716028ee8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254982, encodeId=7f061254982aa, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！, objectType=article, longId=159801, objectId=957315980197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=957315980197, replyNumber=0, likeNumber=70, createdTime=2019-02-13, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=957315980197, moduleTitle=Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=957315980197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254981, encodeId=5c78125498187, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JTO：淋巴细胞浸润、PD-L1、吸烟史之间是何种微妙关系，它们如何影响未曾接受免疫抑制剂治疗的非小细胞肺癌患者的预后？, objectType=article, longId=159657, objectId=718f15965eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=718f15965eed, replyNumber=0, likeNumber=60, createdTime=2019-02-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=718f15965eed, moduleTitle=JTO：淋巴细胞浸润、PD-L1、吸烟史之间是何种微妙关系，它们如何影响未曾接受免疫抑制剂治疗的非小细胞肺癌患者的预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=718f15965eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254980, encodeId=78201254980a2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1/PD-L1肿瘤免疫治疗分子标志物大全, objectType=article, longId=156053, objectId=9faf15605366, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9faf15605366, replyNumber=0, likeNumber=54, createdTime=2018-12-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9faf15605366, moduleTitle=PD-1/PD-L1肿瘤免疫治疗分子标志物大全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9faf15605366)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254979, encodeId=2bbd12549e90e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=EMBO J：VGLL4缺失抑制PD-L1的表达并参与抗肿瘤免疫调控的作用机制, objectType=article, longId=155405, objectId=4c18155405ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c18155405ce, replyNumber=0, likeNumber=56, createdTime=2018-12-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c18155405ce, moduleTitle=EMBO J：VGLL4缺失抑制PD-L1的表达并参与抗肿瘤免疫调控的作用机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c18155405ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254978, encodeId=0b4b12549e878, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=穹兮寰宇叹无穷，参兮纷繁咏何粲-李媛教授细述PD-L1诊断, objectType=article, longId=154770, objectId=4330154e7000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4330154e7000, replyNumber=0, likeNumber=68, createdTime=2018-12-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4330154e7000, moduleTitle=穹兮寰宇叹无穷，参兮纷繁咏何粲-李媛教授细述PD-L1诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4330154e7000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254977, encodeId=67a412549e787, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, objectType=article, longId=154370, objectId=61761543e050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61761543e050, replyNumber=0, likeNumber=49, createdTime=2018-11-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61761543e050, moduleTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61761543e050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254976, encodeId=359412549e612, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=World J Urol：在尿路上皮癌中，PD-1/PD-L1抑制作用的响应预测因子研究, objectType=article, longId=153216, objectId=92ec15321684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ec15321684, replyNumber=0, likeNumber=57, createdTime=2018-11-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ec15321684, moduleTitle=World J Urol：在尿路上皮癌中，PD-1/PD-L1抑制作用的响应预测因子研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92ec15321684)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet：Pembrolizumab可单药治疗低PD-L1 TPS的晚期非小细胞肺癌

2019-04-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：PD-L1基因变异对淋巴瘤PD-1封闭疗法耐药性的影响

2019-04-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的AKT抑制剂ipatasertib联合PD-L1单抗和紫杉醇，显示出对三阴性乳腺癌的治疗前景

2019-04-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

北大BMJ重磅！AIDS是降低全球健康期望寿命的首要原因！NEJM连发2文，PD-1/PD-L1联合治疗大PK！

2019-04-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

宝刀尚未老，新剑已开锋——PD-1/PD-L1抑制剂的现状和新机遇

2019-04-04

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nature Biomedical Engineering：PD-L1棕榈酰化修饰及相应抑制剂开发策略

2019-04-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cancer Immunology Research：发现靶向PD-L1的癌症免疫治疗新途径

2019-04-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

张伟教授：PD-L1检测，挑战重重，任重道远

2019-03-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Commun：吸烟有益免疫治疗？反了！中国科学家发现香烟烟雾会诱导PD-L1表达，帮助癌细胞逃避免疫

2019-03-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准

2019-03-13

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效

2019-03-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Haematol：抗PD-1或抗PD-L1诱发血液系统不良事件罕见

2019-03-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

群雄逐鹿下PD-1/PD-L1专利布局策略

2019-02-19

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！

2019-02-13

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JTO：淋巴细胞浸润、PD-L1、吸烟史之间是何种微妙关系，它们如何影响未曾接受免疫抑制剂治疗的非小细胞肺癌患者的预后？

2019-02-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1/PD-L1肿瘤免疫治疗分子标志物大全

2018-12-19

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

EMBO J：VGLL4缺失抑制PD-L1的表达并参与抗肿瘤免疫调控的作用机制

2018-12-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

穹兮寰宇叹无穷，参兮纷繁咏何粲-李媛教授细述PD-L1诊断

2018-12-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效

2018-11-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

World J Urol：在尿路上皮癌中，PD-1/PD-L1抑制作用的响应预测因子研究

2018-11-12

科室
- - 订阅+
  - 更多科室
工具
服务